Are you Dr. Rodig?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 39 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Brigham & Women's Hospital, Dept. Of Pathology, Amory 3
Boston, MA 02115Phone+1 617-732-7510
Summary
- Dr. Scott Rodig, MD is a board certified pathologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Brigham and Women's Hospital and is an Associate Professor at Harvard Medical School.
Education & Training
Brigham and Women's HospitalResidency, Pathology-Anatomic and Clinical, 1998 - 2002
Washington University in St. Louis School of MedicineClass of 1998
Certifications & Licensure
MA State Medical License 2002 - 2025
American Board of Pathology Anatomic Pathology- American Board of Pathology Hematology
Clinical Trials
- Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors Start of enrollment: 2011 Nov 01
- Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2013 Aug 28
Publications & Presentations
PubMed
- 1 citationsCirculating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab.Jiajia Chen, Giuseppe Tarantino, Mariano Severgnini, Joanna Baginska, Anita Giobbie-Hurder
Oncoimmunology. 2025-12-01 - MAPK pathway activating alteration and immunotherapy efficacy in squamous cell lung carcinoma: results from the randomized, prospective SQUINT trial.Federico Cappuzzo, Biagio Ricciuti, Angelo Delmonte, Laura Bonanno, Xiaoyue Wang
Clinical Cancer Research. 2025-01-21 - A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer.Brandon M Huffman, Osama E Rahma, Kevin Tyan, Yvonne Y Li, Anita Giobbie-Hurder
Cancer Immunology Research. 2025-01-09
Press Mentions
New Research Shows Which Ovarian Cancer Patients Won't Benefit from Immune-PARP ComboMarch 19th, 2020
Research Update: Biomarkers as Predictors of Immunotherapy Response in MelanomaSeptember 13th, 2018
Study Finds Melanoma Biomarkers Predicting Checkpoint Blocker ResponseJuly 18th, 2018- Join now to see all
